Share

Whole Shine Medical Technology Co., Ltd. Stocks

CN¥ 2.67Last Updated 08.04.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 303.93M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 2.67
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rongyu Group Co., Ltd. engages in electrical equipment, credit investigation big data, and banking businesses in China. The company offers electrical equipment products, such as electronic control complete sets, permanent magnet low and high voltage switch products, and electronic energy meters, as well as automatic control system integration services; and credit investigation services. It also provides banking services comprising corporate finance, personal finance, and small and micro finance, as well as financial markets and international banking services; and equipment leasing, real estate leasing, and land use right leasing services. The company was formerly known as Jilin Yongda Group Co., Ltd. and changed its name to Rongyu Group Co., Ltd. in November 2016. Rongyu Group Co., Ltd. was founded in 1986 and is based in Beijing, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overvalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks